Evidence map›Paper›PMID 32042390›Full record

ArticleCaspian journal of internal medicine2020

Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma.

Nazanin Bagherlou, Safar Farajnia, Saber Zahri, Ali Dastranj Tabrizi, Atefeh Nazari

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Caspian journal of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Nazanin BagherlouDepartment of Biology, Faculty of Sciences, University of Mohaghegh Ardabili, Ardabil, Iran.
Safar FarajniaDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Saber ZahriDepartment of Biology, Faculty of Sciences, University of Mohaghegh Ardabili, Ardabil, Iran.
Ali Dastranj TabriziWomen's Reproduction Health Research Center, Tabriz University of Medical Science, Tabriz, Iran.
Atefeh NazariBiotechnology Research Center, Tabriz University of Medical Science, Tabriz, Iran.
University of Mohaghegh Ardabili · IRBiotechnology Research Center · IRTabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian carcinoma is one of the leading causes of cancer-related death among females. K-ras codon 12 mutations are commonly occurring mutations in different types of cancers and leads to resistance against anti-EGFR therapeutics. Hence, determination of mutations in k-ras gene is crucial for predicting response to anti-EGFR therapies. This study aimed to evaluate the prevalence of k-ras gene mutations and CA125 tumor marker in patients with ovarian carcinoma in Tabriz city.

methodsGenomic DNA was extracted from 67 tissues pertained to women with ovarian carcinoma. Mutations in codon 12 and 13 of k-ras gene were analyzed by Nested PCR and RFLP methods. Titer of CA125 tumor marker was determined by ELISA.

resultsAmong the 67 patients, 7 patients (10.4%) had mutation in k-ras codon 12 while none of them had mutation in k-ras codon 13. Based on the results, the frequency of various genotypes were 89.55%, 10.44%, and 0%, for GG, GA, and AA alleles, respectively. The

conclusionThe results in this study indicated high prevalence of k-ras codon 12 mutations and high titer of CA125 tumor marker in patients with ovarian carcinoma in the study region.

Indexed as

CA125Codon 12k-rasOvarian carcinomaRFLP

Identifiers

PMID32042390
PMCPMC6992719
OpenAlexW2997199349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.